期刊文献+

局部进展期中低位直肠癌新辅助治疗后病理消退影响因素分析 被引量:4

Influencing factors of good pathological tumor regression grades after neoadjuvant therapy in locally advanced rectal cancer
下载PDF
导出
摘要 目的 :分析局部进展期中低位直肠癌患者新辅助治疗后病理消退相关影响因素,探讨规范化新辅助治疗对提高局部进展期直肠癌治疗效果的价值。方法:对2002年1月至2009年12月期间122例局部进展期中低位直肠癌患者接受新辅助治疗后行手术的临床资料及术后病理消退分级进行回顾性研究,logistic回归分析与直肠癌新辅助治疗后病理消退相关的影响因素。结果:122例患者中明显病理消退52例,其中完全病理消退11例,病理消退不明显70例。长程放疗方案病理明显消退率高于短中程放疗(60%vs30.56%,P=0.005),同步放化疗病理明显消退率高于单纯放疗(54.05%vs 25%,P=0.002),放疗总量>4 000 cGy病理明显消退率高于总量≤4 000 cGy(60.42%vs 31.08%,P=0.001),logistic回归分析显示同步放化疗及长程放疗是局部进展期直肠癌患者新辅助治疗后病理消退分级的两个独立影响因素(P<0.05)。自2006年1月至2009年12月4年间接受新辅助治疗的直肠癌患者(A组,66例)中同步放化疗、长程放疗、放疗总量达到4 000 cGy以上及术前放化疗后时间间隔达到6周的比率均高于自2002年1月至2005年12月4年间接受新辅助治疗的直肠癌患者(B组,56例)(71.43%vs 51.51%,57.14%vs 27.27%,48.21%vs 30.30%,50%vs 28.79%)。结论:局部进展期中低位直肠癌行长程放疗、同步放化疗临床疗效优于短中程放疗、单纯术前放疗,延长术前同步放化疗后时间间期有提高临床疗效的趋势,规范化术前同步放化疗可提高局部进展期直肠癌患者的临床疗效。 Objective: To analyze the influencing factors of good pathological tumor regression grades after neoadjuvant chemoradiotherapy (CRT) in locally advanced rectal cancer (LARC) and evaluate the value of stan- dardized concurrent preoperative CRT in improving the clinical efficacy in LARC. Methods: A total of 122 patients with LARC receiving neoadjuvant CRT between January 2002 and December 2009 were analyized retrospectively. The tumor regression grades (TRG) were detected by HE staining. Logistic regression analysis was used to evaluate the influencing factors associated with clinical efficacy after neoadjuvant CRT in LARC. Results: Fifty-two patients reached good TRG, including 11 patients with pathological complete response, 70 patients were poorly responsive to radiation. The good response rate after long-course radiation therapy (RT) was significantly higher than that of patients who underwent short/medium course RT (60% vs 30.56%, P=0.005), the good response rate with concurrent preoperative CRT was significantly higher than that of patients with preop- erative RT alone (54.05% vs 25%, P=0.002), the good response rate after RT dose〉4 000 cGy was significantly higher th~:.!hat of patients underwent RT dose ≤ 4 000 cGy(60.42% vs 31.08%,P=0.001). Logistic regression analysis showed the concurrent preoperaticve CRT and long-course RT were independently :associated with theclinical efficacy in LARC after neoadjuvant CRT. The rate of patients received concurrent preoperative CRT, long- course RT, RT dose〉4 000 cGy and the interval between neoadjuvant CRT and surgery ≥ 6 weeks between January 2006 and December 2009 was significantly higher than that of patients between January 2002 and December 2005 (71.43% vs 51.51%, 57.14% vs 27.27%, 48.21% vs 30.30%, 50.0% vs 28.79%). Conclusion: Concurrent preoperative CRT and long-course RT provide higher good response rate, standardized preoperative concurrent CRT may improve the clinical efficacy in patients with LACR.
出处 《温州医学院学报》 CAS 2014年第4期235-240,共6页 Journal of Wenzhou Medical College
基金 国家自然科学基金资助项目(30973460 81272561) 温州市科技局科研基金资助项目(Y20100021)
关键词 直肠肿瘤 病理消退 新辅助治疗 影响因素 rectal neoplasm tumor regression grades neoadjuvant chemoradiotherapy clinical influencingfactors
  • 相关文献

参考文献14

  • 1Mohiuddin M, Mohiuddin MM, Marks J, et al. Future direc- tions in neoadjuvant therapy of rectal cancer: Maximizing pathological complete response rates[J]. Cancer Treat Rev, 2009, 35(7): 547-552.
  • 2Dworak O, Keilholz L, Hoffmann A. Pathological features of rectal cancer after preoperative radiochemotherapy[J]. Int J Colorectal Dis, 1997, 12(1): 19-23.
  • 3柴瑞,于志奇,傅传刚,王颢,张卫,刘连杰,张畅.多药耐药蛋白4与直肠癌放疗敏感性关系的初步研究[J].中华胃肠外科杂志,2011,14(8):627-630. 被引量:10
  • 4胡芝,柯晓慧,黄一统,叶琼,孙杭临.p27在宫颈鳞癌放疗前后的表达及临床意义[J].温州医学院学报,2007,37(2):162-164. 被引量:1
  • 5Gerard JP, Conroy T, Bonnetain F, et al. Preoperative ra- diotherapy with or without concurrent fluorouracil and leu- covorin in T3-4 rectal cancers: results of FFCD 9203[J]. J Clin Oncol, 2006, 24(28): 4620-4625.
  • 6Latkauskas T, Paskauskas S, Dambrauskas Z, et al. Preop- erative chemoradiation vs radiation alone for stage II and I]I resectable rectal cancer: a meta-analysis[J]. Colorectal Dis, 2010, 12(11): 1075-1083.
  • 7Gerard JP, Azria D, Gourgou-Bourgade S, et al. Clinical out- come of the ACCORD 12/0405 PRODIGE 2 randomized trial in rectal cancer[J]. J Clin Oncol, 2012, 30(36): 4558- 4565.
  • 8Aschele C, Cionini L, Lonardi S, et al. Primary tumor re- sponse to preoperative chemoradiation with or without oxaliplatin in locally advanced rectal cancer: pathologic results of the STAR-01 randomized phase III trial[J]. J Clin Oncol, 2011, 29(20): 2773-2780.
  • 9Roh MS, Colangelo LH, O'Connell M J, et al. Preoperative multimodality therapy improves disease-free survival in pa- tients with carcinoma of the rectum: NSABP R-03[J]. J Clin Oncol, 2009, 27(31): 5124-5130.
  • 10Rodel C, Liersch T, Becker H, et al. Preoperative chemor- adiotherapy and postoperative chemotherapy with fluorou- racil and oxaliplatin versus fluorouracil alone in locally ad- vanced rectal cancer: initial results of the German CAO/ ARO/AIO-04 randomised phase 3 trial[J]. Lancet Oncol, 2012, 13(7): 679-687.

二级参考文献29

  • 1宋继荣,高玉莲,胡玉红,何红.p27^(kip1)在宫颈癌组织中的表达及意义[J].中国妇产科临床杂志,2004,5(2):132-134. 被引量:2
  • 2于月成,李红梅,辛晓燕,赵海波,李奇灵,党艳丽.宫颈癌中p27基因的表达及其临床意义[J].细胞与分子免疫学杂志,2004,20(6):730-732. 被引量:3
  • 3Sandur SK, Deorukhkar A, Pandey MK, et al. Curcumin modulates the radiosensitivity of colorectal cancer ceils by suppressing constitutive and inducible NF-kappaB activity. Int J Radiat Oncol Biol Phys, 2009,75(2):534-542.
  • 4Komuro Y, Watanabe T, Tsurita G, et al. Expression pattern of telomerase reverse transcriptase in recta| carcinoma predicts tumor radiosensitivity, local recurrence and disease-free survival. Hepatogastroenterology, 2005,52(64) :985-989.
  • 5Wu XY, Xu Z, Chen C, et al. Growth hormone receptor overexpression predicts response of rectal cancers to preoperative radiotherapy. Eur J Cancer, 2006,42(7):888-894.
  • 6Schwartz JL, Rasey J, Wiens L,et al. Functional inactivation of p53 by HPV-E6 transformation is associated with a reduced expression of radiation-induced potentially lethal damage. Int J Radiat, 1999,75(3) :285 -291.
  • 7Chin KV, Ueda K, Pastanl I, et al. Modulation of active of the promoter of the human MDR1 gene by Ras and p53. Science, 1992,255(5043):459-462.
  • 8Russel FG, Koenderink JB, Masereeuw R. Muhidrug resistance protein 4 (MRP4/ABCC4): a versatile efflux transporter for drugs and signalling molecules. Trends in Pharmacol Sci, 2008,29(4) : 200-207.
  • 9Gradilone A, Puleinelli FM, Lotti LV, et al. Celecoxib upregulates muhidrug resistance proteins in colon cancer: lack of synergy with standard chemotherapy. Curr Cancer Drug Targets, 2008,8(5) :414-420.
  • 10Stammler G, Pommerenke EW, Mattern J, et al. Effects of single doses of irradiation of on the expression of resistance- related proteins in murine NIH 3T3 and human lung carcinoma cells. Carcinogenesis, 1995,16(9) :2051-2055.

共引文献9

同被引文献36

引证文献4

二级引证文献9

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部